Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2(+)/HER2(-) advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
    Meeting Abstract

    Xu, R. H.; Ajani, J. A.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D.; Enzinger, P. C.; Ilson, D. H.; Kim, S.; Lordick, F.; Shitara, K.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
    Meeting Abstract

    Qin, S.; Tabernero, J.; van Cutsem, E.; Fuchs, C. S.; Janjigian, Y. Y.; Bhagia, P.; Li, K.; Adelberg, D.; Bang, Y. J.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemo in early triple-negative breast cancer (TNBC)
    Meeting Abstract

    Saji, S.; Mittendorf, E.; Harbeck, N.; Zhang, H.; Barrios, C. H.; Hegg, R.; Koehler, A.; Sohn, J.; Iwata, H.; Telli, M. L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
    Meeting Abstract

    Masuda, N.; Hurvitz, S.; Vahdat, L.; Harbeck, N.; Wolff, A. C.; Tolaney, S. M.; Loi, S.; O'Shaughnessy, J.; Xie, D.; Walker, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
    Meeting Abstract

    Saji, S.; Llombart Cussac, A.; Andre, F.; Robson, M. E.; Harbeck, N.; Schmid, P.; Cescon, D. W.; Ahn, J. S.; Nanda, R.; Fan, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study)
    Meeting Abstract

    Chiu, C. F.; Yeh, Y. M.; Yeh, K. H.; Desai, J.; Price, T. J.; Tebbutt, N.; Tabernero, J.; Velez, L.; Trevino, T. L.; Grothey, A.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Palliation for all people: Alleviating racial disparities in supportive care for brain metastases
    Editorial

    Wilcox, J. A.; Boire, A. A.
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • LY6K promotes glioblastoma tumorigenicity via CAV-1 mediated ERK1/2 signaling enhancement
    Journal Article

    Sastry, N. G.; Wan, X.; Huang, T.; Alvarez, A. A.; Pangeni, R. P.; Song, X.; James, C. D.; Horbinski, C. M.; Brennan, C. W.; Nakano, I.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • Rare cancer on the rise: An educational review of breast implant-associated anaplastic large cell lymphoma
    Review

    Mitry, M. A.; Sogani, J.; Sutton, E. J.; Kumar, P.; Horwitz, S.; Elmi, A.; Patel, S. N.; Gallagher, K.; Dashevsky, B. Z.; Mango, V.
    Journal of Breast Imaging (2020)

    Fulltext@MSK | Save
  • Changing the language of how we measure and report smoking status: Implications for reducing stigma, restoring dignity, and improving the precision of scientific communication
    Editorial

    Williamson, T. J.; Riley, K. E.; Carter-Harris, L.; Ostroff, J. S.
    Nicotine & Tobacco Research (2020)

    Fulltext@MSK | Save